GT Medical Technologies Announces Publication of Data Showing Company’s Targeted Therapy is Effective for Treating Recurrences of Common Type of Brain Tumor

TEMPE, Ariz.–(BUSINESS WIRE)–GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced positive results from a clinical trial supporting the efficacy and safety profile of a new treatment, GammaTile™ Therapy, for patients with recurrent, previously treated brain tumors known as meningiomas. Meningiomas are the most common type of primary brain tumor. They are usually non-cancerous but can have a significant impact on patients’ lives, causing headaches, seizures, cognitive decline, and other life-threatening symptoms. Results were published in the Journal of Neurosurgery (JNS), the official journal of the American Association of Neurological Surgeons.